文献速递肺结节与肺癌

Sunvozertinib 治疗中国铂类经治 EGFR 外显子20插入突变晚期非小细胞肺癌(WU-KONG6):单臂、开放、多中心2期试验

Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2023-12-12

WU-KONG6 是一项在中国37家中心开展的单臂、开放、多中心2期试验,评估 Sunvozertinib 300 mg 每日一次治疗铂类经治、局部晚期或转移性 EGFR 外显子20插入突变非小细胞肺癌的疗效与安全性。97例可评估患者中确认客观缓解率为61%(95%CI 50–71),均为部分缓解,安全性总体可控。

要点

  • 铂类经治 EGFR 外显子20插入突变晚期 NSCLC 中,Sunvozertinib 确认 ORR 达61%(95%CI 50–71)。
  • 300 mg 每日一次耐受性良好,最常见≥3级治疗相关不良事件为血肌酸磷酸激酶升高17%。
  • 常见严重治疗相关不良事件包括间质性肺病5%、贫血3%、呕吐2%、恶心2%和肺炎2%。

核心结论

  • 在铂类化疗经治的 EGFR 外显子20插入突变局部晚期或转移性 NSCLC 患者中,Sunvozertinib 显示出抗肿瘤疗效且安全性可控。

研究设计与样本

  • WU-KONG6 为单组、开放、多中心2期试验,在中国37家医疗中心开展。
  • 纳入病理或细胞学确诊的局部晚期或转移性 NSCLC 且肿瘤组织携带 EGFR 外显子20插入突变的成人患者。
  • 所有患者既往至少接受过一线全身治疗,其中至少一线含铂类化疗。
  • 患者接受 Sunvozertinib 300 mg 每日一次直至符合方案停药标准。
  • 主要终点为独立评审委员会评估的客观缓解率(ORR),缓解需至少间隔4周的两次评估确认。

主要发现

  • 2021年7月19日至2022年5月6日共入组104例患者。
  • 97例可评估疗效患者中,59例(61%)达到肿瘤缓解,确认 ORR 为61%(95%CI 50–71),全部为部分缓解。
  • 肿瘤缓解在不同年龄、性别、吸烟史、EGFR 外显子20插入亚型、基线脑转移、既往治疗线数及免疫治疗史患者中均观察到。
  • 300 mg 每日一次耐受性良好;最常见≥3级治疗相关不良事件为血肌酸磷酸激酶升高18例(17%)、腹泻8例(8%)、贫血6例(6%)。

关键数值与推荐

  • 确认 ORR 为61%(95%CI 50–71),基于97例可评估疗效患者。
  • 常见严重治疗相关不良事件:间质性肺病5例(5%)、贫血3例(3%)、呕吐2例(2%)、恶心2例(2%)、肺炎2例(2%),基于104例安全性分析人群。

临床怎么用

  • 对于铂类经治、携带 EGFR 外显子20插入突变的局部晚期或转移性 NSCLC 患者,Sunvozertinib 300 mg 每日一次可作为候选治疗选择。
  • 治疗期间需关注血肌酸磷酸激酶升高、腹泻、贫血等治疗相关不良事件,以及间质性肺病等严重不良事件。

局限性

  • 本研究为单臂、开放标签2期试验,无随机对照。
  • 原文未报告与对照组的比较数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sunvozertinib is an oral, irreversible, and selective tyrosine kinase inhibitor that has a favourable safety profile and encouraging antitumour activity, as shown in phase 1 studies of patients with heavily pretreated non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation (exon20ins). We aimed to assess the antitumour efficacy of sunvozertinib in patients with platinum-pretreated locally advanced or metastatic NSCLC with EGFR exon20ins. METHODS: WU-KONG6 is a single-group, open-label, multicentre phase 2 trial of sunvozertinib monotherapy, conducted across 37 medical centres in China. We enrolled adult patients with pathologically or cytologically confirmed locally advanced or metastatic NSCLC whose tumour tissue carried an EGFR exon20ins mutation. All patients had received at least one line of previous systemic therapy, with at least one line containing platinum-based chemotherapy. The primary endpoint was objective response rate (ORR), as assessed by the independent review committee. The ORR was defined as the percentage of patients who achieved complete or partial response, confirmed by two separate assessments with at least 4-week time interval, until disease progression or initiation of any new anti-cancer therapy. Enrolled patients received sunvozertinib 300 mg once daily until meeting discontinuation criteria per the protocol. Patients who received at least one dose of treatment and were evaluable for efficacy analysis were included in the primary analysis, and all patients who received at least one dose of treatment were included in the safety analysis. This study is registered with ChinaDrugTrials.org, CTR20211009, and ClinicalTrials.gov, NCT05712902, and efficacy and safety follow-up are ongoing. FINDINGS: Between July 19, 2021, and May 6, 2022, 104 patients were enrolled. At data cutoff (Oct 17, 2022), the last enrolled patient had been followed up for about 6 months. Among 97 patients evaluable for efficacy analysis, 59 (61%) patients achieved tumour response, with a confirmed ORR of 61% (95% CI 50-71). All tumour responses were partial responses. Tumour responses were observed irrespective of age, sex, smoking history, EGFR exon20ins subtypes, brain metastasis at baseline, previous lines of therapy, and history of onco-immunotherapy. In total, 19 death events occurred over a median follow-up period of 7·6 months (IQR 6·1-9·4). Sunvozertinib was well tolerated at 300 mg once daily. The most common grade 3 or worse treatment-related adverse events were blood creatine phosphokinase increased (18 [17%] of 104), diarrhoea (eight [8%]), and anaemia (six [6%]). The most common serious treatment-related adverse events were interstitial lung disease (five [5%] of 104), anaemia (three [3%]), vomiting (two [2%]), nausea (two [2%]) and pneumonia (two [2%]). INTERPRETATION: In this phase 2 study, sunvozertinib demonstrated antitumour efficacy in patients with platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins, with a manageable safety profile. A multinational randomised, phase 3 study of sunvozertinib versus platinum-doublet chemotherapy in EGFR exon20ins NSCLC is ongoing (NCT05668988). FUNDING: Dizal Pharmaceutical.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2023. PMID: 38101437. doi:10.1016/S2213-2600(23)00379-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。